JNJ Quote, Financials, Valuation and Earnings

Biogen has a net margin of 50.24% compared to Johnson & Johnson's net margin of 9.89%. Johnson & Johnson's return on equity of 30.18% beat Biogen's return on equity of 9.11%.

Johnson & Johnson has a consensus price target of $170.19, signalling upside risk potential of 10.36%. On the other hand Biogen has an analysts' consensus of $172.25 which suggests that it could grow by 45.76%. Given that Biogen has higher upside potential than Johnson & Johnson, analysts believe Biogen is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.425, which suggesting that the stock is 57.471% less volatile than S&P 500. In comparison Biogen has a beta of 0.125, suggesting its less volatile than the S&P 500 by 87.479%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.22%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $21.9B, which are larger than Biogen quarterly revenues of $2.4B. Johnson & Johnson's net income of $11B is higher than Biogen's net income of $240.5M. Notably, Johnson & Johnson's price-to-earnings ratio is 17.15x while Biogen's PE ratio is 11.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.19x versus 1.76x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 50.24% compared to Johnson & Johnson's net margin of 19.72%. Johnson & Johnson's return on equity of 30.18% beat Gilead Sciences's return on equity of 32.29%.

Johnson & Johnson has a consensus price target of $170.19, signalling upside risk potential of 10.36%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 18.71%. Given that Gilead Sciences has higher upside potential than Johnson & Johnson, analysts believe Gilead Sciences is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.425, which suggesting that the stock is 57.471% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.22%. Gilead Sciences offers a yield of 3.2% to investors and pays a quarterly dividend of $0.79 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Johnson & Johnson quarterly revenues are $21.9B, which are larger than Gilead Sciences quarterly revenues of $6.7B. Johnson & Johnson's net income of $11B is higher than Gilead Sciences's net income of $1.3B. Notably, Johnson & Johnson's price-to-earnings ratio is 17.15x while Gilead Sciences's PE ratio is 20.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.19x versus 4.25x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 50.24% compared to Johnson & Johnson's net margin of 21.68%. Johnson & Johnson's return on equity of 30.18% beat Eli Lilly and's return on equity of 78.25%.

Johnson & Johnson has a consensus price target of $170.19, signalling upside risk potential of 10.36%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 33.25%. Given that Eli Lilly and has higher upside potential than Johnson & Johnson, analysts believe Eli Lilly and is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.425, which suggesting that the stock is 57.471% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.22%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $21.9B, which are larger than Eli Lilly and quarterly revenues of $12.7B. Johnson & Johnson's net income of $11B is higher than Eli Lilly and's net income of $2.8B. Notably, Johnson & Johnson's price-to-earnings ratio is 17.15x while Eli Lilly and's PE ratio is 59.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.19x versus 13.54x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 50.24% compared to Johnson & Johnson's net margin of -907.48%. Johnson & Johnson's return on equity of 30.18% beat Moderna's return on equity of -29.23%.

Johnson & Johnson has a consensus price target of $170.19, signalling upside risk potential of 10.36%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 93.66%. Given that Moderna has higher upside potential than Johnson & Johnson, analysts believe Moderna is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.425, which suggesting that the stock is 57.471% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.22%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $21.9B, which are larger than Moderna quarterly revenues of $107M. Johnson & Johnson's net income of $11B is higher than Moderna's net income of -$971M. Notably, Johnson & Johnson's price-to-earnings ratio is 17.15x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.19x versus 3.01x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.